The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

SARS-CoV-2 Neutralisation Assay Development Kit
Now Available

To support the characterisation of SARS-CoV-2 variants, The Native Antigen Company now offers an RBD-ACE2 Neutralisation Assay Development Kit. Including all the key reagents required to measure Spike-antibody binding, this easy-to-use kit can be used to identify and qualitatively assess the ability of antibodies to neutralise RBD-ACE2 interactions. For more information on this kit, please see the data below:

Neutralisation Assay: Competitive Binding of ACE2 Against Anti-SARS-CoV-2 Sera

RBD-ACE2 Kit Data [Landing Page]

Binding rate (B/B0%) for negative samples is ≥ 60%. Binding rate for strongly positive samples is ≤ 50%. Borderline samples, with moderate neutralization, may be assessed with binding rates between 50-60. Negative and positive control antibodies were included. SARS-CoV-2 serum samples #1, #2 and #3 are < 50% and considered strongly positive indicating SARS-CoV-2 neutralizing antibody is present in these samples. Samples #4, #5 and #6 are derived from SARS patient sera, and show binding of >50%, indicating moderate or negative neutralizing capacity.

To support the characterisation of SARS-CoV-2 variants, The Native Antigen Company has since developed an extended range of variant RBD-ACE2 Neutralisation Assay Development Kits, including:

Indian Variant
South African Variant
Brazilian Variant
UK Variant

To see our full range of kits, click the button below:

Got any questions?

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

15 + 3 =